蒿甲醚-本芴醇对奈韦拉平处置的药物遗传学影响:临床显著药物相互作用?
在尼日利亚成年HIV感染者中,采用两阶段、单序列交叉设计,研究蒿甲醚-本芴醇对奈韦拉平药代动力学的影响及七种SNP背景。关键药代参数变化无临床显著性,90%CI完全落在0.80-1.25无效应界内;但谷浓度低于3400 ng/ml最低有效浓度的患者比例从10%升至21%。
要点
- 蒿甲醚-本芴醇未显著改变奈韦拉平关键药代参数,90%CI在0.80-1.25内。
- 联用后奈韦拉平谷浓度低于3400 ng/ml者从10%增至21%。
- 快代谢者中谷浓度不达标风险额外增加,联用时需关注。
核心结论
- 蒿甲醚-本芴醇对奈韦拉平关键药代参数无临床显著影响,90%CI完全落在0.80-1.25无效应界内。
- 联用后奈韦拉平谷浓度低于3400 ng/ml最低有效浓度的患者比例从10%升至21%,快代谢者风险额外增加。
研究设计与样本
- 两阶段、单序列交叉研究,纳入150名接受奈韦拉平为基础抗逆转录病毒方案的HIV感染成年尼日利亚患者。
- 第一阶段对七种SNP进行基因分型并用稀疏采样识别与奈韦拉平血浆浓度独立相关的SNP,按等位基因数分为弱、中间和快代谢者。
- 第二阶段患者接受标准蒿甲醚-本芴醇联合奈韦拉平治疗,第3天进行密集药代动力学采样。
主要发现
- 奈韦拉平关键药代参数变化无临床显著性,90%CI完全落在0.80-1.25无效应界内。
- 谷浓度低于3400 ng/ml最低有效浓度的患者比例从无蒿甲醚-本芴醇时的10%(均为快代谢者)增至联用时的21%(快代谢者14%、中间代谢者4%、弱代谢者3%)。
关键数值与推荐
- 奈韦拉平最低有效谷浓度为3400 ng/ml。
- 无临床显著变化判定标准为90%CI完全落在0.80-1.25无效应界内。
临床怎么用
- 奈韦拉平与蒿甲醚-本芴醇联用时,应关注谷浓度不达标风险,尤其快代谢者。
- 联用期间可考虑监测奈韦拉平谷浓度以确保高于3400 ng/ml最低有效浓度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: In this study the influence of first-line antimalarial drug artemether-lumefantrine on the pharmacokinetics of the antiretroviral drug nevirapine was investigated in the context of selected single nucleotide polymorphisms (SNPs) in a cohort of adult HIV-infected Nigerian patients. METHODS: This was a two-period, single sequence crossover study. In stage 1, 150 HIV-infected patients receiving nevirapine-based antiretroviral regimens were enrolled and genotyped for seven SNPs. Sparse pharmacokinetic sampling was conducted to identify SNPs independently associated with nevirapine plasma concentration. Patients were categorized as poor, intermediate and extensive metabolizers based on the numbers of alleles of significantly associated SNPs. Intensive sampling was conducted in selected patients from each group. In stage 2, patients received standard artemether-lumefantrine treatment with nevirapine, and intensive pharmacokinetic sampling was conducted on day 3. RESULTS: No clinically significant changes were observed in key nevirapine pharmacokinetic parameters, the 90% confidence interval for the measured changes falling completely within the 0.80-1.25 no-effect boundaries. However, the number of patients with trough plasma nevirapine concentration below the 3400 ng ml-1 minimum effective concentration increased from 10% without artemether-lumefantrine (all extensive metabolizers) to 21% with artemether-lumefantrine (14% extensive, 4% intermediate, and 3% poor metabolizers). CONCLUSIONS: This approach highlights additional increase in the already existing risk of suboptimal trough plasma concentration, especially in extensive metabolizers when nevirapine is co-administered with artemether-lumefantrine.
引用
- Abdullahi ST, Olagunju A, Soyinka JO, et al. Pharmacogenetics of artemether-lumefantrine influence on nevirapine disposition: Clinically significant drug-drug interaction? Br J Clin Pharmacol. 2019. PMID: 30471138. doi:10.1111/bcp.13821
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。